Skip to main content

Home/ Cancer/ Group items tagged medicine research virus

Rss Feed Group items tagged

Matti Narkia

Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatme... - 0 views

  •  
    Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers.
    Reddy PS, Burroughs KD, Hales LM, Ganesh S, Jones BH, Idamakanti N, Hay C, Li SS, Skele KL, Vasko AJ, Yang J, Watkins DN, Rudin CM, Hallenbeck PL.
    J Natl Cancer Inst. 2007 Nov 7;99(21):1623-33. Epub 2007 Oct 30.
    PMID: 17971529
    doi:10.1093/jnci/djm198
Matti Narkia

Phase I trial of Seneca Valley Virus (NTX-010), a newly discovered systemically deliver... - 0 views

  •  
    Phase I trial of Seneca Valley Virus (NTX-010), a newly discovered systemically deliverable oncolytic picornavirus, in patients with solid tumors with neuroendocrine features.
    C. M. Rudin, D. Lansey, K. D. Burroughs, L. M. Hales, J. R. Neefe, P. S. Reddy and P. L. Hallenbeck
    Johns Hopkins Univ, Baltimore, MD; Neotropix, Inc., Malvern, PA.
    Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition).
    Vol 25, No 18S (June 20 Supplement), 2007: 18014
    © 2007 American Society of Clinical Oncology.

    Conclusions: NTX-010 is a novel first-in-class anticancer virus with selective tropism for tumors with neuroendocrine features. This is the first anticancer virus given intravenously with documented selective intratumoral infection and replication. Administration was well tolerated. Safety data and viral kinetics will be presented.

1 - 2 of 2
Showing 20 items per page